These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 29454676)

  • 1. OPA1: How much do we know to approach therapy?
    Del Dotto V; Fogazza M; Lenaers G; Rugolo M; Carelli V; Zanna C
    Pharmacol Res; 2018 May; 131():199-210. PubMed ID: 29454676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OPA1 gene therapy prevents retinal ganglion cell loss in a Dominant Optic Atrophy mouse model.
    Sarzi E; Seveno M; Piro-Mégy C; Elzière L; Quilès M; Péquignot M; Müller A; Hamel CP; Lenaers G; Delettre C
    Sci Rep; 2018 Feb; 8(1):2468. PubMed ID: 29410463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eight human OPA1 isoforms, long and short: What are they for?
    Del Dotto V; Fogazza M; Carelli V; Rugolo M; Zanna C
    Biochim Biophys Acta Bioenerg; 2018 Apr; 1859(4):263-269. PubMed ID: 29382469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dominant optic atrophy: Culprit mitochondria in the optic nerve.
    Lenaers G; Neutzner A; Le Dantec Y; Jüschke C; Xiao T; Decembrini S; Swirski S; Kieninger S; Agca C; Kim US; Reynier P; Yu-Wai-Man P; Neidhardt J; Wissinger B
    Prog Retin Eye Res; 2021 Jul; 83():100935. PubMed ID: 33340656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OPA1 mutations associated with dominant optic atrophy impair oxidative phosphorylation and mitochondrial fusion.
    Zanna C; Ghelli A; Porcelli AM; Karbowski M; Youle RJ; Schimpf S; Wissinger B; Pinti M; Cossarizza A; Vidoni S; Valentino ML; Rugolo M; Carelli V
    Brain; 2008 Feb; 131(Pt 2):352-67. PubMed ID: 18222991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitochondrial dysfunction in an Opa1(Q285STOP) mouse model of dominant optic atrophy results from Opa1 haploinsufficiency.
    Kushnareva Y; Seong Y; Andreyev AY; Kuwana T; Kiosses WB; Votruba M; Newmeyer DD
    Cell Death Dis; 2016 Jul; 7(7):e2309. PubMed ID: 27468686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary mtDNA defects do not cause optic nerve dysfunction in a mouse model of dominant optic atrophy.
    Yu-Wai-Man P; Davies VJ; Piechota MJ; Cree LM; Votruba M; Chinnery PF
    Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4561-6. PubMed ID: 19443720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitochondrial DNA content is decreased in autosomal dominant optic atrophy.
    Kim JY; Hwang JM; Ko HS; Seong MW; Park BJ; Park SS
    Neurology; 2005 Mar; 64(6):966-72. PubMed ID: 15781809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitochondrial dynamics and disease, OPA1.
    Olichon A; Guillou E; Delettre C; Landes T; Arnauné-Pelloquin L; Emorine LJ; Mils V; Daloyau M; Hamel C; Amati-Bonneau P; Bonneau D; Reynier P; Lenaers G; Belenguer P
    Biochim Biophys Acta; 2006; 1763(5-6):500-9. PubMed ID: 16737747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modelling autosomal dominant optic atrophy associated with OPA1 variants in iPSC-derived retinal ganglion cells.
    Sladen PE; Jovanovic K; Guarascio R; Ottaviani D; Salsbury G; Novoselova T; Chapple JP; Yu-Wai-Man P; Cheetham ME
    Hum Mol Genet; 2022 Oct; 31(20):3478-3493. PubMed ID: 35652445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OPA1-associated disorders: phenotypes and pathophysiology.
    Amati-Bonneau P; Milea D; Bonneau D; Chevrollier A; Ferré M; Guillet V; Gueguen N; Loiseau D; de Crescenzo MA; Verny C; Procaccio V; Lenaers G; Reynier P
    Int J Biochem Cell Biol; 2009 Oct; 41(10):1855-65. PubMed ID: 19389487
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Nitta Y; Osaka J; Maki R; Hakeda-Suzuki S; Suzuki E; Ueki S; Suzuki T; Sugie A
    Elife; 2024 Aug; 12():. PubMed ID: 39177028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic screening for OPA1 and OPA3 mutations in patients with suspected inherited optic neuropathies.
    Yu-Wai-Man P; Shankar SP; Biousse V; Miller NR; Bean LJ; Coffee B; Hegde M; Newman NJ
    Ophthalmology; 2011 Mar; 118(3):558-63. PubMed ID: 21036400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The molecular mechanisms of OPA1-mediated optic atrophy in Drosophila model and prospects for antioxidant treatment.
    Yarosh W; Monserrate J; Tong JJ; Tse S; Le PK; Nguyen K; Brachmann CB; Wallace DC; Huang T
    PLoS Genet; 2008 Jan; 4(1):e6. PubMed ID: 18193945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of OPA1 mutations on mitochondrial morphology and apoptosis: relevance to ADOA pathogenesis.
    Olichon A; Landes T; Arnauné-Pelloquin L; Emorine LJ; Mils V; Guichet A; Delettre C; Hamel C; Amati-Bonneau P; Bonneau D; Reynier P; Lenaers G; Belenguer P
    J Cell Physiol; 2007 May; 211(2):423-30. PubMed ID: 17167772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in Mitochondrial Morphology and Bioenergetics in Human Lymphoblastoid Cells With Four Novel OPA1 Mutations.
    Kao SH; Yen MY; Wang AG; Yeh YL; Lin AL
    Invest Ophthalmol Vis Sci; 2015 Apr; 56(4):2269-78. PubMed ID: 25744979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OPA1 mutations induce mitochondrial DNA instability and optic atrophy 'plus' phenotypes.
    Amati-Bonneau P; Valentino ML; Reynier P; Gallardo ME; Bornstein B; Boissière A; Campos Y; Rivera H; de la Aleja JG; Carroccia R; Iommarini L; Labauge P; Figarella-Branger D; Marcorelles P; Furby A; Beauvais K; Letournel F; Liguori R; La Morgia C; Montagna P; Liguori M; Zanna C; Rugolo M; Cossarizza A; Wissinger B; Verny C; Schwarzenbacher R; Martín MA; Arenas J; Ayuso C; Garesse R; Lenaers G; Bonneau D; Carelli V
    Brain; 2008 Feb; 131(Pt 2):338-51. PubMed ID: 18158317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OPA1 (Kjer type) dominant optic atrophy: a novel mitochondrial disease.
    Delettre C; Lenaers G; Pelloquin L; Belenguer P; Hamel CP
    Mol Genet Metab; 2002 Feb; 75(2):97-107. PubMed ID: 11855928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OPA1 haploinsufficiency due to a novel splicing variant resulting in mitochondrial dysfunction without mitochondrial DNA depletion.
    Sun C; Wu X; Bai HX; Wang C; Liu Z; Yang C; Lu Y; Jiang P
    Ophthalmic Genet; 2021 Feb; 42(1):45-52. PubMed ID: 33251885
    [No Abstract]   [Full Text] [Related]  

  • 20.
    Cartes-Saavedra B; Lagos D; Macuada J; Arancibia D; Burté F; Sjöberg-Herrera MK; Andrés ME; Horvath R; Yu-Wai-Man P; Hajnóczky G; Eisner V
    Proc Natl Acad Sci U S A; 2023 Mar; 120(12):e2207471120. PubMed ID: 36927155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.